Edited by Paolo A. Ascierto, Carlo Bifulco, Sandra Demaria, Reinhard Dummer, Patrick Hwu, Francesco Marincola, Giuseppe Masucci, Iman Osman, Igor Puzanov.
Volume 19 Supplement 1
Immunotherapy Bridge 2020 and Melanoma Bridge 2020: meeting abstracts
Publication of this supplement has not been supported by sponsorship. Some Supplement Editors declare potential competing interest, as follow: Paolo A. Ascierto (Consulting fee: BMS, Roche, Array, Novartis, Merck Serono, Pierre Fabre, Incyte, Newlinks Genetics, Genmab, Medimmune, Sindax, AstraZeneca, Sun Pharma, Sanofi, Idera, Ultimovacs, Sandoz, Immunocore, 4SC, Alkermes, Italfarmaco, Nektar, Eisai, Regeneron, Daiichi Sankyo, Pfizer, Oncosec, Nouscom, Takis, Lunaphore - Contracted Research: BMS, Roche, Array - Travel support: MSD) - Carlo Bifulco (Consultant/advisory relationship: PrimeVax, BMS, Ventana, HalioDx; Stock Ownership: PrimeVax; Patent US20180322632A1: Image processing systems and methods for displaying multiple images of a biological specimen) - Sandra Demaria (grant to Institution from Lytix Biopharma and Nanobiotix, honorarium for advisory/consulting from Lytix Biopharma, Ono Pharmaceutical, and EMD Serono) - Patrick Hwu (Scientific Advisory Board: Immatics, Dragonfly) - Igor Puzanov (consulting: Amgen, Merck, Iovance).
Virtual2-5 December 2020
Citation: Journal of Translational Medicine 2021 19(Suppl 1):110
Annual Journal Metrics
8 days to first decision for all manuscripts (Median)
45 days to first decision for reviewed manuscripts only (Median)
4,155,992 Downloads (2021)
7,409 Altmetric mentions (2021)